

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/128853 A2

- (51) **International Patent Classification:**
C12N 15/113 (2010.01) *A61K 31/7088* (2006.01)
- (21) **International Application Number:**
PCT/US2024/059822
- (22) **International Filing Date:**
12 December 2024 (12.12.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/609,567 13 December 2023 (13.12.2023) US
- (71) **Applicant: ULTRAGENYX PHARMACEUTICAL INC.** [US/US]; 60 Leveroni Court, Novato, California 94949 (US).
- (72) **Inventors: SWISTOWSKI, Andrzej;** c/o Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, California 94949 (US). **DINDOT, Scott Victor;** c/o Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, California 94949 (US). **COUTHOUIS, Julien;** c/o Ultragenyx

Pharmaceutical Inc., 60 Leveroni Court, Novato, California 94949 (US). **ATWOOD, Heather Richbourg;** c/o Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, California 94949 (US).

(74) **Agent: ZHANG, Clark et al.;** Goodwin Procter LLP, IP Docketing Dept./7th Fl, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) **Title:** COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH UBE3A OVEREXPRESSION




FIG. 8

(57) **Abstract:** This application provides antisense nucleic acid compounds that reduce *UBE3A* mRNA levels and/or *UBE3A* polypeptide levels in central nervous system neurons, thereby alleviating effects and symptoms caused by excess *UBE3A* levels. The application further provides compositions comprising antisense nucleic acid compounds and their use in methods of preventing or treating conditions associated with excess *UBE3A* mRNA and/or *UBE3A* polypeptide levels in a subject.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*